Persistence of Human Papillomavirus, Overexpression of p53, and Outcomes of Patients After Endoscopic Ablation of Barrett's Esophagus  Shanmugarajah Rajendra,

Slides:



Advertisements
Similar presentations
Risk of Neoplasia After Colectomy in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Lauranne A.A.P. Derikx, Loes H.C.
Advertisements

Risk of Esophageal Adenocarcinoma and Mortality in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis  Marjolein Sikkema, Pieter.
Esophageal Adenocarcinoma
Sachin Wani, Dayna Early, Steve Edmundowicz, Prateek Sharma 
Abnormal Liver Tests and Fatty Liver on Ultrasound
Romy E. Verbeek, Lisanne F. Spittuler, Anique Peute, Martijn G. H
Saurabh Dawra, Vishal Sharma, Usha Dutta 
How to Manage a Barrett's Esophagus Patient With Low-Grade Dysplasia
Millie D. Long, Bruce E. Sands 
Herbert C. Wolfsen, Michael B. Wallace  Gastroenterology 
Safety and Efficacy of Endoscopic Mucosal Therapy With Radiofrequency Ablation for Patients With Neoplastic Barrett's Esophagus  William J. Bulsiewicz,
Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis 
High In-hospital Mortality After Percutaneous Endoscopic Gastrostomy: Results of a Nationwide Population-based Study  Gaurav Arora, Don Rockey, Samir.
Pichamol Jirapinyo, Christopher C. Thompson 
Survival of Patients With Superficial Esophageal Adenocarcinoma After Endoscopic Treatment vs Surgery  Saowanee Ngamruengphong, Herbert C. Wolfsen, Michael.
Patrick Yachimski, Gary W. Falk 
Patrick Yachimski, Gary W. Falk 
Diffuse Gastric Wall Thickening: Appearances Can Be Deceptive
Volume 142, Issue 2, Pages (February 2012)
Endoscopic Ultrasound Does Not Accurately Stage Early Adenocarcinoma or High- Grade Dysplasia of the Esophagus  Patrick E. Young, Andrew B. Gentry, Ruben.
Patients With Barrett’s Esophagus and Persistent Low-grade Dysplasia Have an Increased Risk for High-grade Dysplasia and Cancer  Christine Kestens, G.
Judy A. Trieu, Mohammad Bilal, Ali Hashmi 
Issue Highlights Clinical Gastroenterology and Hepatology
Outcomes of Endoscopic Submucosal Dissection vs Esophagectomy for T1 Esophageal Squamous Cell Carcinoma in a Real-World Cohort  Yiun Zhang, Han Ding,
Miles Basil, Anita Pudusseri, Robert Lowe 
Distribution of Body Fat and Its Influence on Esophageal Inflammation and Dysplasia in Patients With Barrett's Esophagus  Eric M. Nelsen, Yujiro Kirihara,
Endoscopic Ultrasound–Fine-Needle Biopsy Is Superior to Endoscopic Ultrasound– Fine-Needle Aspiration in Sampling Pancreatic Masses  Fan Wang, MD, Hong-Ling.
Prateek Sharma, MD, Sachin Wani, MD, Amit Rastogi, MD 
Volume 143, Issue 3, Pages e1 (September 2012)
Activity-Based Costing and Management in a Hospital-Based GI Unit
Risk of Nonmelanoma Skin Cancer in Patients With Inflammatory Bowel Disease Who Use Thiopurines Is Not Increased  Fiona D.M. van Schaik, Martijn G.H.
Risk of Esophageal Adenocarcinoma and Mortality in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis  Marjolein Sikkema, Pieter.
An Association Between Microscopic Colitis and Celiac Disease
Endoscopic Therapy for Barrett's Esophagus
Amie L. Harvey, Tommy Yen, Anand Kunda 
AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review  Jean-Frederic Colombel,
Efficacy and Durability of Radiofrequency Ablation for Barrett's Esophagus: Systematic Review and Meta-analysis  Eric S. Orman, Nan Li, Nicholas J. Shaheen 
Joanna Gibson, Jill Lacy, Ellen Matloff, Marie Robert 
DNA Methylation Alterations In Endoscopic Retrograde Cholangiopancreatography Brush Samples of Patients With Suspected Pancreaticobiliary Disease  Mansour.
Human Papillomavirus–Related Rectal Squamous Cell Carcinoma in a Patient With Ulcerative Colitis Diagnosed on Narrow-Band Imaging  Ivana Dzeletovic, Shabana.
Abnormal Liver Tests and Fatty Liver on Ultrasound
Thurarshen Jeyalingam, Yuto Shimamura, Christopher Teshima 
Ramesh Kumar, Masiullah, Pintu Kumar Singh 
Circumferential Balloon-based Radiofrequency Ablation of Barrett's Esophagus With Dysplasia Can Be Simplified, yet Efficacy Maintained, by Omitting the.
Dushyant Singh, Reetu Singh, Wendell K. Clarkston 
Patients With Nondysplastic Barrett's Esophagus Have Low Risks for Developing Dysplasia or Esophageal Adenocarcinoma  Sachin Wani, Gary Falk, Matthew.
George N. Ioannou, Meaghan F. Splan, Noel S. Weiss, George B
Evaluation of the Patient-Reported Outcomes Measurement Information System in a Large Cohort of Patients With Inflammatory Bowel Diseases  Michael D.
David H. Bruining, William J. Sandborn 
Najat Mourra, Nikias Colignon  Clinical Gastroenterology and Hepatology 
Eric S. Orman, Marwan Ghabril, Naga Chalasani 
Factors Associated With Progression of Barrett’s Esophagus: A Systematic Review and Meta-analysis  Rajesh Krishnamoorthi, Siddharth Singh, Karthik Ragunathan,
Incidence of Progression of Persistent Nondysplastic Barrett’s Esophagus to Malignancy  Yonne Peters, Judith Honing, Wietske Kievit, Christine Kestens,
Kamal V. Patel, Rishi M. Goel, Terry Wong 
A Young Woman With Gallstone Pancreatitis and Abnormal Liver Tests: When Is Endoscopic Retrograde Cholangiopancreatography Needed?  Andrew D. Rhim, Michael.
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn’s Disease and Effects of Natalizumab Therapy  Emanuelle Bellaguarda, Kian.
Issue Highlights Clinical Gastroenterology and Hepatology
Nicolas Williet, William J. Sandborn, Laurent Peyrin–Biroulet 
A 27-Year-Old Woman With Constipation: Diagnosis and Treatment
Coagulation in Liver Disease: A Guide for the Clinician
Issue Highlights Clinical Gastroenterology and Hepatology
Adherence to Biopsy Guidelines for Barrett's Esophagus Surveillance in the Community Setting in the United States  Julian A. Abrams, Robert C. Kapel,
Issue Highlights Clinical Gastroenterology and Hepatology
Prateek Sharma, Gary W. Falk, Allan P
Adverse Outcomes: Why Bad Things Happen to Good People
Ajaypal Singh, John D. Christein, Shyam Varadarajulu 
Low-grade dysplasia in Barrett’s esophagus
Medical Therapy for Refractory Pediatric Crohn’s Disease
M. Babitha Reddy, David M. Poppers, Cora Uram–Tuculescu 
Karanprit Singh, Prateek Chapalamadugu, Peter Malet 
Presentation transcript:

Persistence of Human Papillomavirus, Overexpression of p53, and Outcomes of Patients After Endoscopic Ablation of Barrett's Esophagus  Shanmugarajah Rajendra, Bin Wang, Darren Pavey, Prateek Sharma, Tao Yang, Cheok Soon Lee, Neil Gupta, Madeleine J. Ball, Raghubinder Singh Gill, Xiaojuan Wu  Clinical Gastroenterology and Hepatology  Volume 13, Issue 7, Pages 1364-1368.e5 (July 2015) DOI: 10.1016/j.cgh.2014.11.017 Copyright © 2015 AGA Institute Terms and Conditions

Figure 1 HR-HPV/P53 (IHC) status and treatment outcome after endoscopic ablative therapy in BD/EAC patients. No BD/EAC recurrence was detected during the course of the study. LGD, low-grade dysplasia. Clinical Gastroenterology and Hepatology 2015 13, 1364-1368.e5DOI: (10.1016/j.cgh.2014.11.017) Copyright © 2015 AGA Institute Terms and Conditions

Figure 2 ISH detection of transcriptional activity of hr-HPV 16 and 18 E6/E7 mRNA in (A) HPV16+ cervical squamous cell carcinoma, (B) HPV16+ head and neck squamous cell carcinoma; (C) HPV-16/18 positive EAC, and (D) Barrett’s esophagus with HGD. Positive staining is diffusely present in the nuclei and cytoplasm as punctate/granular appearance. (E) HPV DNA negative samples of EAC and (F) Barrett’s HGD. No signals were detected in (E) and (F). Clinical Gastroenterology and Hepatology 2015 13, 1364-1368.e5DOI: (10.1016/j.cgh.2014.11.017) Copyright © 2015 AGA Institute Terms and Conditions

Supplementary Figure 1 Rate of clearance of disease and abnormal laboratory results after RFA in patients with different pretreatment laboratory results. Hazard ratios estimated by using Cox proportional hazards regression, adjusted for number of RFA treatments (log transformed) (hazard ratio, 0.53; 95% CI, 0.35–0.82; P = .002), body mass index (hazard ratio, 0.68; 95% CI, 0.31–1.47; P = .41), and male gender (hazard ratio, 1.48; 95% CI, 1.05–1.77; P = .019) with body mass index a time-variable covariate (hazard ratio, 1.36; 95% CI, 1.08–1.46; P = .002), with each covariate being a standardized normal transformation of the raw covariate ([value-mean]/standard deviation); P values corrected for multiple comparisons by using the Holm method. Note that hazard ratio greater than 1.00 indicates faster clearance of disease, whereas hazard ratio less than 1.00 indicates slower clearance of disease. Two patients in the p53 IHC positive group were excluded from this analysis because no biopsies were available before 24 months and 33 months after first ablation. The time-to-event analysis indicates that clearance of disease was slower in HGD and EAC compared with LGD. Clearance of disease was slower when transcriptionally active HPV was present and also when p53 IHC was positive compared with patients without these abnormal laboratory results at the pre-ablation biopsies. When either biologically active HPV or p53 overexpression was initially present, the rate of clearance of the abnormal histologic results and laboratory results appeared to be similar (hazard ratio, 1.10; 95% CI, 0.71–1.71; P = .67; n = 26). Clinical Gastroenterology and Hepatology 2015 13, 1364-1368.e5DOI: (10.1016/j.cgh.2014.11.017) Copyright © 2015 AGA Institute Terms and Conditions